Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bilici

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Neoplasma|November 23, 2011
Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experienceM Ozkan, V Berk, M A Kaplan, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|July 19, 2011
Is there any correlation among adiponectin levels in serum, tumor tissue and normal tissue of the same patients wih breast cancer?B Sonmez, M Seker, A Bilici, et al.
Nigerian Journal of Clinical Practice|May 6, 2025
Assessing the Efficacy and Safety of Shorter versus Extended Adjuvant Treatment Duration for Stage III Low-Risk Colon Cancer: A Comparative AnalysisN O Kalkan, G Ucar, S A Esen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerR Dent, F André, A Gonçalves, et al.
Cancer Chemotherapy and Pharmacology|November 1, 2018
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomesEce Esin, B Oksuzoglu, A Bilici, et al.
Breast (Edinburgh, Scotland)|April 14, 2026
Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposureF Kemik, T K Şahin, H Özçelik, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Neoplasma|November 23, 2011
Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experienceM Ozkan, V Berk, M A Kaplan, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|July 19, 2011
Is there any correlation among adiponectin levels in serum, tumor tissue and normal tissue of the same patients wih breast cancer?B Sonmez, M Seker, A Bilici, et al.
Nigerian Journal of Clinical Practice|May 6, 2025
Assessing the Efficacy and Safety of Shorter versus Extended Adjuvant Treatment Duration for Stage III Low-Risk Colon Cancer: A Comparative AnalysisN O Kalkan, G Ucar, S A Esen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerR Dent, F André, A Gonçalves, et al.
Cancer Chemotherapy and Pharmacology|November 1, 2018
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomesEce Esin, B Oksuzoglu, A Bilici, et al.
Breast (Edinburgh, Scotland)|April 14, 2026
Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposureF Kemik, T K Şahin, H Özçelik, et al.
Pageof 4